The estimated Net Worth of Sangeeta N. Bhatia is at least $9.33 Million dollars as of 30 August 2024. Sangeeta Bhatia owns over 646 units of Vertex Pharmaceuticals stock worth over $2,412,154 and over the last 9 years he sold VRTX stock worth over $6,384,561. In addition, he makes $530,103 as Independent Director at Vertex Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Sangeeta Bhatia VRTX stock SEC Form 4 insiders trading
Sangeeta has made over 23 trades of the Vertex Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 646 units of VRTX stock worth $98,670 on 30 August 2024.
The largest trade he's ever made was exercising 10,753 units of Vertex Pharmaceuticals stock on 5 January 2018 worth over $1,362,190. On average, Sangeeta trades about 2,123 units every 98 days since 2015. As of 30 August 2024 he still owns at least 5,081 units of Vertex Pharmaceuticals stock.
You can see the complete history of Sangeeta Bhatia stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sangeeta Bhatia biography
Dr. Sangeeta N. Bhatia, M.D., Ph.D. is Independent Director of Vertex Pharmaceuticals Incorporated. Dr. Bhatia is a professor at the Massachusetts Institute of Technology, or MIT, where she currently serves as the John J. and Dorothy Wilson Professor of Health Sciences & Technology/Electrical Engineering & Computer Science. For the 2018 year, Dr. Bhatia was on sabbatical from MIT while she served as a co-founder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring. Prior to joining MIT in 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego from 1998 through 2005. Dr. Bhatia also is an investigator for the Howard Hughes Medical Institute, a member of the Department of Medicine at Brigham and Women’s Hospital, a member of the Broad Institute and a member of the Koch Institute for Integrative Cancer Research. Dr. Bhatia holds a Sc.B. in biomedical engineering from Brown University, an S.M. and Ph.D. in Mechanical Engineering from MIT and an M.D. from Harvard Medical School.
What is the salary of Sangeeta Bhatia?
As the Independent Director of Vertex Pharmaceuticals, the total compensation of Sangeeta Bhatia at Vertex Pharmaceuticals is $530,103. There are 16 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
How old is Sangeeta Bhatia?
Sangeeta Bhatia is 51, he's been the Independent Director of Vertex Pharmaceuticals since 2015. There are 17 older and 6 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
What's Sangeeta Bhatia's mailing address?
Sangeeta's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Insiders trading at Vertex Pharmaceuticals
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden, and Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
What does Vertex Pharmaceuticals's logo look like?
Complete history of Sangeeta Bhatia stock trades at Vertex Pharmaceuticals
Vertex Pharmaceuticals executives and stock owners
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jeffrey Leiden,
Executive Chairman of the Board -
Stuart Arbuckle,
Executive Vice President, Chief Commercial Officer -
Reshma Kewalramani,
President, Chief Executive Officer, Director -
Amit Sachdev,
Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO -
David Altshuler,
Executive Vice President - Global Research, Chief Scientific Officer -
Michael Parini,
Executive Vice President, Chief Legal and Administrative Officer -
Dr. Reshma Kewalramani FASN, M.D.,
CEO, Pres & Director -
Charles Wagner,
Chief Financial Officer, Executive Vice President -
Paul Silva,
Senior Vice President, Controller -
Dr. Jeffrey Marc Leiden M.D., Ph.D.,
Exec. Chairman -
Stuart A. Arbuckle B.Sc.,
Exec. VP & COO -
Dr. David M. Altshuler,
Exec. VP of Global Research & Chief Scientific Officer -
Charles F. Wagner Jr.,
Exec. VP & CFO -
Bruce Sachs,
Co-Lead Independent Director -
Margaret McGlynn,
Independent Director -
Terrence Kearney,
Independent Director -
Sangeeta Bhatia,
Independent Director -
Yuchun Lee,
Independent Director -
William Young,
Independent Director -
Alan Garber,
Independent Director -
lloyd Carney,
Independent Director -
Michael Partridge,
Vice President - Investor Relations -
Diana McKenzie,
Independent Director -
Nia Tatsis,
Senior Vice President, Chief Regulatory Officer -
John Gray,
Senior Vice President, Genetic Therapies -
Gerald Bruce,
Executive Vice President, Commercial Operations -
Carmen Bozic,
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer -
Joy Liu,
Sr. VP & Gen. Counsel -
Damian W. Wilmot Esq.,
Sr. VP, Chief Risk and Compliance Officer -
Mike Tirozzi,
SVP and Chief Information & Data Officer -
Kristen Ambrose,
Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services -
Joshua S Boger,
Chairman & CEO -
Elaine Ullian,
Director -
Ian F Smith,
SVP & CFO -
Jeffrey Chodakewitz,
SVP GMDA, CMO -
Thomas Graney,
Chief Financial Officer -
Michel Lagarde,
Director -
Wayne Joseph Riley,
Director -
Peter Mueller,
CSO & SVP Drug Discovery -
Thomas Connolly,
SVP, Human Resources -
Kenneth L Horton,
EVP & Chief Legal Officer -
Megan E Pace,
SVP, Corp. Communications -
Christiana Stamoulis,
SVP, Corp Strategy & Bus Devlp -
Matthew Emmens,
Director -
Lisa Kelly,
SVP, Human Resources -
Dennis L Winger,
Director -
Eugene Cordes,
Director -
Nancy Wysenski,
EVP & Chief Commercial Officer -
David T Howton,
SVP -
Kenneth S Boger,
SVP & General Counsel -
Kurt Graves,
EVP, Chief Commercial Officer -
John J Alam,
SVP, Drug Eval. & Appr. -
Stuart J Collinson,
Director -
Charles A Sanders,
Director -
Roger W Brimblecombe,
Director -
Freda C Lewis Hall,
EVP, Medicines Development -
Eve Elizabeth Slater,
Director -
Richard C Garrison,
SVP, Organizational Developmen -
Johanna Messina Power,
Controller -
Victor A Hartmann,
EVP, Strategic & Corp. Devlp. -
Eric Brandt,
Director -
Lynne H Brum,
VP, Corp. Comm.&Financial Plan -
Paul A Negulescu,
VP, Research -
John F Niblack,
Director -
Iain P M Buchanan,
VP, European Operations -
Vicki L Sato,
President -
N Anthony Coles,
SVP, Comm. Ops. -
Bastiano Sanna,
EVP, Cell & Genetic Therapies -
Joy Liu,
SVP, General Counsel -
Kristen Ambrose,
SVP & Chief Accounting Officer -
Suketu Upadhyay,
Director -
Jonathan Biller,
EVP and Chief Legal Officer -
Nancy Thornberry,
Director -
Edward Morrow Iii Atkinson,
EVP, Chief Technical Ops. Off. -
Jennifer Schneider,
Director